On January 11, 2021, a new version of the Nomenclature of Medical Biology Acts (NABM068) was released. One new code for detecting the genome of the influenza A and B viruses by RT-PCR was introduced.
The test for detecting the genome of the influenza A and B viruses by RT-PCR is included in the NABM under the code 5272. The test is indicated for symptomatic patients in combination with the detection of the SARS-CoV-2 genome by gene amplification techniques (5271) or the detection of SARS-CoV-2 antigens by rapid diagnostic techniques (4274). This test can only be presented for reimbursement during co-circulation of the SARS-CoV-2 virus and influenza viruses, especially during the epidemic period of seasonal influenza as defined by the National Public Health Agency. The reimbursement tariff is €16.20.
The new version of NABM can be downloaded here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).